Bausch & Lomb Corp (BLCO) · Oct 28, 2026 · Earnings
Beat — Adjusted EPS $0.34 vs ~$0.21 consensus
Bausch + Lomb’s Q3 earnings beat on adjusted EPS, with all three segments growing and full-year EBITDA guidance raised sharply.
Bausch + Lomb is executing a broad-based eye-health growth plan across contact lenses, surgical products and pharmaceuticals, with MIEBO, premium intraocular lenses and daily contact lenses among the current growth drivers. Its stated longer-term plan targets 5–7% constant-currency revenue growth and margin expansion through 2028.
The quarter materially exceeded the earnings bar. Adjusted EPS was $0.34 versus published consensus of roughly $0.21, while revenue of $1.375 billion was essentially in line with the roughly $1.37 billion expectation.
| Metric | Q3 2026 | Q3 2025 | External expectation |
|---|---|---|---|
| Revenue | $1.375B | $1.281B | ~$1.37B |
| Adjusted EPS | $0.34 | $0.18 | ~$0.21 |
| Adjusted EBITDA | $325M | $243M | — |
| Operating cash flow | $233M | $137M | — |
| Full-year revenue guidance | $5.450B–$5.550B | — | Prior: $5.440B–$5.540B |
| Full-year adjusted EBITDA excluding acquired IPR&D | $1.090B–$1.140B | — | Prior: $1.025B–$1.075B |
Growth was broad rather than dependent on one segment. Vision Care rose 5% reported and 6% constant currency, Surgical increased 9%, and Pharmaceuticals grew 11%, with the company citing daily SiHy and ULTRA contact lenses, premium IOLs and MIEBO as key drivers.
The more important surprise is operating leverage. Operating income rose to $155 million from $95 million, adjusted EBITDA climbed to $325 million from $243 million, and operating cash flow increased to $233 million from $137 million.
Management raised the full-year outlook beyond the prior quarter’s increase. Revenue guidance moved only modestly higher, but adjusted EBITDA guidance jumped by $65 million at both ends of the range, implying that the company sees stronger underlying performance and profitability rather than merely better currency. The filing says the revenue range includes a $15 million improvement in the underlying business outlook, partly offset by $5 million less expected currency benefit.
Bottom line: This is a meaningful upgrade to the business story: revenue landed near expectations, but profitability and cash generation materially outperformed, prompting another sizable EBITDA guidance increase. The quarter strengthens the case that Bausch + Lomb’s growth plan is translating into operating leverage, not just sales growth.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!